ONCTERNAL THERAPEUTICS INC (ONCT)

US68236P1075 - Common Stock

0.31  0 (-0.03%)

Premarket: 0.303 -0.01 (-2.26%)

ONCTERNAL THERAPEUTICS INC

NASDAQ:ONCT (9/27/2023, 7:00:02 PM)

Premarket: 0.303 -0.01 (-2.26%)

0.31

0 (-0.03%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)11-01 2023-11-01/amc
Ins Owners1.76%
Inst Owners16.66%
Market Cap18.28M
Shares58.97M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts74.55
IPO02-03 2004-02-03
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ONCT Daily chart

Company Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 30 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

Company Info

ONCTERNAL THERAPEUTICS INC

12230 El Camino Real, Suite 230

San Diego CALIFORNIA 92130

P: 18584341113.0

CEO: James B. Breitmeyer

Employees: 30

Website: https://www.oncternal.com/

ONCT News

News Image21 days ago - Oncternal TherapeuticsOncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image2 months ago - Oncternal TherapeuticsOncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who...

News Image2 months ago - Oncternal TherapeuticsOncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image3 months ago - Oncternal TherapeuticsOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image4 months ago - Oncternal TherapeuticsOncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image4 months ago - Oncternal TherapeuticsOncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT Twits

Here you can normally see the latest stock twits on ONCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example